What is Opticyte?
Opticyte is a pioneering healthcare technology firm that has engineered the VitalO2, a groundbreaking device capable of measuring intracellular oxygen levels in real-time. This innovation addresses a critical gap in the clinical management of sepsis and organ failure, conditions that frequently result in high mortality rates. By providing clinicians with immediate, actionable data, the company aims to standardize care and mitigate healthcare disparities, particularly among marginalized populations. The technology is specifically designed for high-acuity environments, including emergency departments and operating rooms, where rapid intervention is essential for patient survival.
How much funding has Opticyte raised?
Opticyte has raised a total of $4.6M across 2 funding rounds:
Grant
$2.9M
Angel/Seed
$1.7M
Grant (2020): $2.9M with participation from SBIR Phase IIB
Angel/Seed (2020): $1.7M led by Starfish Medical and SWAN Venture Fund II
Key Investors in Opticyte
Starfish Medical
A leading medical device design and development firm that provides comprehensive engineering services to help companies bring complex healthcare technologies to market.
SWAN Venture Fund II
An investment vehicle focused on supporting early-stage companies with high-growth potential in the healthcare and life sciences sectors.
SBIR Phase IIB
A federal grant program designed to support the research and development of innovative technologies with significant commercial potential.
What's next for Opticyte?
With this major enterprise-level funding, Opticyte is poised to accelerate the clinical validation and commercial deployment of its VitalO2 platform. The company will likely prioritize scaling its manufacturing capabilities and expanding its footprint within major hospital networks. As the firm transitions from development to market penetration, the focus will remain on securing regulatory milestones and demonstrating the long-term efficacy of its diagnostic tools in reducing mortality associated with systemic organ failure. This capital infusion provides the necessary runway to refine its go-to-market strategy and solidify its role in advancing health equity through technological precision.
See full Opticyte company page
